丨2026年8月6日星期四丨 NO.1 礼来:上半年替尔泊肽大卖277亿美元,中国区收入增长73% 8月5日,礼来披露半年度业绩,公司上半年实现总营收427.73亿美元,同比增长49%。从地区分布来看,上半年美国市场收入265.32亿美元,同比增长37%,中国市场收入16.35亿美元,同比增长73%。上半年,礼来8款核心产品合计收入290.77亿美元,占总营收68%。其中GLP-1类药物替尔泊...
Source Link丨2026年8月6日星期四丨 NO.1 礼来:上半年替尔泊肽大卖277亿美元,中国区收入增长73% 8月5日,礼来披露半年度业绩,公司上半年实现总营收427.73亿美元,同比增长49%。从地区分布来看,上半年美国市场收入265.32亿美元,同比增长37%,中国市场收入16.35亿美元,同比增长73%。上半年,礼来8款核心产品合计收入290.77亿美元,占总营收68%。其中GLP-1类药物替尔泊...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.